Takeda
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Takeda sits in the top decile of US sponsors by registered trial count (#88 of 15,742 sponsors by registered trial count).
Takeda: 408 sponsored US clinical trials, 49 recruiting.
Takeda sponsors 408 registered US clinical trials on ClinicalTrials.gov, 49 of them currently recruiting, and 284 completed. 174 of these trials are in Phase 3-4 (later-stage) and 209 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy Volunteers, with 16 trials.
Top-decile sponsor footprint
Takeda ranks in the top decile of sponsors by registered trial count (#88 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
284 of 340 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (83.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
408 total, page 6 of 9
Safety, Tolerability and Pharmacokinetic Study of Multiple Rising Doses of TAK- 063 in Participants With Stable Schizophrenia and Healthy Participants
NCT01879722
Comparison of Fasiglifam (TAK-875) With Sitagliptin When Used in Combination With Metformin in Patients With Type 2 Diabetes
NCT01834274
The Influence of Febuxostat on Coronary Artery Endothelial Dysfunction in Participants With Chronic Stable Angina
NCT01763996
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
NCT01829464
Comparison of TAK-875 to Placebo as an Add-on to Glimepiride in Patients With Type 2 Diabetes
NCT01829477
Phase 1b Study Investigating Safety & Immunogenicity of TDV Given Intradermally by Needle or Needle-Free PharmaJet Injector
NCT01765426
Impact of SC vs IM Administration of DENVax (TDV) on Safety and Immunogenicity
NCT01728792
A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma
NCT01712490
A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
NCT01564537
Safety and Efficacy Study of Ramelteon (TAK-375) Tablets for Sublingual Administration (SL) in Adults With Bipolar 1 Disorder
NCT01677182
Norovirus Bivalent-Vaccine Efficacy Study
NCT01609257
Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules for Healing of Erosive Esophagitis and Maintenance of Healed Erosive Esophagitis and Relief of Heartburn in Adolescents
NCT01642615
Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules in Treating Symptomatic Non-Erosive Gastroesophageal Reflux Disease in Adolescents
NCT01642602
Effect of Febuxostat Compared to Placebo on Exercise Tolerance in Participants With Chronic Stable Angina
NCT01549977
Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease
NCT01609582
Drug Interaction Study of Colchicine and Theophylline
NCT01601132
Efficacy of Lu AA21004 on Cognitive Dysfunction in Major Depressive Disorder
NCT01564862
Comparison of Fasiglifam (TAK-875) to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes
NCT01549964
Comparison of Efficacy and Safety of TachoSil® Versus Surgicel® Original for the Secondary Hemostatic Treatment of Needle Hole Bleeding in Vascular Surgery
NCT01500135
A Comparison of the Safety and Immunogenicity of Various Schedules of Dengue Vaccine in Healthy Adult Volunteers
NCT01542632
Effect of Febuxostat on Blood Pressure
NCT01496469
TAK-875 Glimepiride Drug-Interaction Study
NCT01496443
Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes
NCT01481116
Efficacy and Safety of Azilsartan Medoxomil Used in Combination With Metformin in Participants With Hypertension and Diabetes
NCT01496430
Efficacy and Safety of Ramelteon Sublingual as Adjunctive Therapy for Maintenance Treatment of Bipolar I Disorder
NCT01467713
Efficacy and Safety of Ramelteon Sublingual in Adult Patients With Acute Depressive Episodes Associated With Bipolar I Disorder
NCT01467700
Study to Assess the Effects of Daily Administration of Pioglitazone on Brain Hemodynamics in Healthy Elderly Participants
NCT01456117
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
NCT01456195
Conversion Study From Epoetin Alfa to Monthly Peginesatide Injection in Patients With Chronic Kidney Disease on Dialysis
NCT01478971
Efficacy and Safety of TAK-875 in Combination With Sitagliptin in Participants With Type 2 Diabetes Mellitus
NCT01414920
VELVET, a Dose Range Finding Trial of Veltuzumab in Subjects With Moderate to Severe Rheumatoid Arthritis
NCT01390545
Vortioxetine (Lu AA21004) 10 and 20 mg for Treatment of Major Depressive Disorder With Sexual Dysfunction
NCT01364649
Effects of Vortioxetine (Lu AA21004) on the Concentrations of Selected Neurotransmitters in Healthy Male Adults
NCT01299805
TAK-329 Glucose Clamp Study
NCT01311076
Effect of Dexlansoprazole on Bone Homeostasis
NCT01216293
Bivalent Norovirus Vaccine Study
NCT01168401
An Extension Study of HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Idursulfase-IT in Conjunction With Elaprase in Pediatric Participants With Hunter Syndrome and Cognitive Impairment
NCT01506141
Safety and Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder
NCT01179516
TachoSil® Versus Surgicel® Original for the Secondary Treatment of Local Bleeding in Adult and Pediatric Patients Undergoing Hepatic Resection Surgery
NCT01192022
Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder
NCT01163266
Safety and Efficacy of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder
NCT01153009
Healthy and Renal Impairment Study of Colcrys (Colchicine, USP)
NCT01084278
A Comparative Single-Dose Pharmacokinetic (PK) and Safety Study of Azilsartan Medoxomil in Children With Hypertension and in Healthy Adults
NCT01078376
Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES)
NCT01101035
Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment
NCT01082640
Study to Evaluate the Pharmacokinetics and Safety of Dexlansoprazole in Pediatric Subjects With Symptomatic Gastroesophageal Reflux Disease
NCT01045096
Effect of Febuxostat on Joint Damage in Hyperuricemic Subjects With Early Gout
NCT01078389
Febuxostat Versus Allopurinol or Placebo in Patients With Hyperuricosuria and Calcium Oxalate Stones
NCT01077284
Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Moderate to Severe Hypertension.
NCT01033071
Efficacy and Safety of TAK-875 in Subjects With Type 2 Diabetes Mellitus
NCT01007097
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 119 |
| Phase 2 | 90 |
| Phase 3 | 148 |
| Phase 4 | 26 |
What is open in the Takeda pipeline
49 recruiting of 408 indexed (12% open); 284 completed (70%).
Phase mix: 174 late (III/IV) vs 209 early (I/II) (balanced across stages).
Top condition: Healthy Volunteers (16 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Takeda: open-pipeline peers nationwide
Peers matched on 408 registered trials and 12% open enrollment, not the therapeutic-area sidebar.
Takeda sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 408 trials (± recruiting share)
- University of Kansas Medical Center · 408 trials · 23% recruiting
- Case Comprehensive Cancer Center · 407 trials · 14% recruiting
- University of Nebraska · 407 trials · 13% recruiting
- St. Jude Children's Research Hospital · 410 trials · 22% recruiting
Sponsors near 12% open enrollment (± trial volume)
- Arcus Biosciences · 12% recruiting · 25 trials
- Ardelyx · 12% recruiting · 25 trials
- Kyowa Kirin Co. · 12% recruiting · 25 trials
- East Carolina University · 12% recruiting · 58 trials
Related
What to do with this Takeda page
408 registered trials is a research-attention snapshot, not an endorsement of Takeda or any single study.
- 49 of Takeda's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Healthy Volunteers is the condition Takeda studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy Volunteers trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Takeda pipeline card: 408 registered trials from official public datasets.Report a data error.